01
01
inno.N holds outstanding competitiveness
in both the technologies it applies and the products
it offers in the markets for prescription drugs,
health products and beauty products.
Prescription Drugs
HEALTH
BEAUTY
R&D
Through ongoing R&D,
inno.N re-writes the history of rising to the challenge.
-
Novel Drug
Research Center The Center conducts research on innovative, novel drugs with global demand, focusing on the treatment of gastrointestinal diseases, immune diseases and cancer. -
Bio
Research Center The Center conducts research on not only vaccines to prevent infection but also next generation cell and gene therapy. -
Health & Beauty
Research Center The Center conducts research focused on materials and ingredients that are individually recognized, as well as health functional foods to present a new standard in the market for health and beauty products.
ESG
Heal the World for a Better Life
inno.N is committed to the values of promoting the health of mankind and sustainability of the environment.
The company practices these values based on the belief that it has a social responsibility towards the community that it is a member of.
-
Ethical
Management Corporate social responsibility is practiced by promoting fair competition and transparent business management. -
Social
Contribution Through unique social contribution activities,
inno.N delivers happiness to local communities
and helps create a healthier world. -
Environmental
Management A work environment based on a system that systematically promotes safety, health
and the environment has been set up
and is continuously promoted. -
Governance To build further trust from shareholders and stakeholders, inno.N publicly discloses its governance in a transparent manner.
Financial information
View moreNEWS
- HK inno.N and TABUK PARTNER TO BRING K-CAB®(TEGOPRAZAN) AN INNOVATIVE MEDICINE TO THE MENA REGION. 2024.04.23
- HK inno.N confirmed nonclinical efficacy of its novel EGFR-mutated NSCLC treatment 2024.04.23
- HK inno.N presents research findings for EGFR-mutated NSCLC treatment at the AACR in the U.S. 2024.04.03